Clinical trials performed in both healthy adult volunteers and patients with hereditary TTR-mediated amyloidosis (hATTR), have shown that patisiran was able to consistently and specifically reduce serum TTR protein levels and tissue TTR protein deposits (known as amyloid), the hallmark of the pathology. The gene discussed is TTR; the disease is familial amyloid neuropathy.